Amarillo Biosciences, Inc. company was founded in 1984 and is based in Amarillo, Texas. Amarillo Biosciences, Inc. (AMAR) is engaged in developing biologics for the treatment of human and animal diseases. The Company has a technology for a less toxic method of administration, low-dose oral interferon, in United States Food and Drug Administration (FDA) Phase II clinical trials. The Company has developed a dietary supplement and an interferon alpha lozenge, but, as of December 31, 2008, had not commenced any product commercialization activities. Injectable interferon is an immune modulator used to treat viral and autoimmune diseases and cancer. Orally delivered interferon binds to mucosal cells in the mouth and throat resulting in stimulation of immune mechanisms, and has been shown to activate hundreds of immune system genes in the peripheral blood. As of December 31, 2008, the Company has a Phase II study in progress in the United States to treat oral warts in human immunodeficiency virus-positive (HIV+) patients (Orphan Drug Designation).